Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| SMX | Smx (Security Matters) Public | $17.40 | $11.49 | 194.42% | 22.4M | $6.2M | $3.12$66,187.27 |
| AMBR | Amber International | $2.47 | $0.89 | 56.33% | 89.6M | $136.6M | $1.23$13.09 |
| MNDR | Mobile-health Network Solutions | $2.65 | $0.75 | 39.47% | 21.5M | $2.3M | $1.53$40.00 |
| VRCA | Verrica Pharmaceuticals | $6.71 | $1.59 | 31.05% | 1.2M | $48.6M | $3.28$13.60 |
| OSS | One Stop Systems | $5.95 | $1.34 | 29.07% | 3.9M | $113.0M | $1.85$7.20 |
| LGHL | Lion Group | $7.12 | $1.49 | 26.41% | 52.2K | $15.6M | $3.93$213.20 |
| MFI | mF International | $20.50 | $4.24 | 26.08% | 139.1K | $26.9M | $4.08$60.73 |
| ARWR | Arrowhead Pharmaceuticals | $57.71 | $10.92 | 23.34% | 7.1M | $6.5B | $9.57$59.15 |
| IRWD | Ironwood Pharmaceuticals | $3.86 | $0.73 | 23.32% | 5.8M | $509.2M | $0.53$5.13 |
| SUPX | SuperX Ai Technology | $27.04 | $5.09 | 23.19% | 331.5K | $590.3M | $2.75$76.50 |
Related Articles
Featured Article
A Quiet AI Stock -- SuperX AI Technology (SUPX) -- Is Up Over 770% in 2025. Here's 1 Key Reason Why It's Getting Attention.
Selena Maranjian|Nov 24, 2025
This company is a very early-stage AI business. It could skyrocket over the coming years, but it might not.
This Undervalued Stock Is Up Over 1,000% This Year. Here's 1 Key Reason Why the Run May Continue
Manali Pradhan, CFA|Nov 9, 2025
Picking a small stake in early stage AI infrastructure players can prove a smart move for investors with above-average risk appetite.
This Small AI Stock Has Outpaced Nvidia. 1 Reason Why It's Still Rising.
Stefon Walters|Oct 22, 2025
This company's path to profitability is getting a lot clearer.
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround
Alex Carchidi|Jun 12, 2023
Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned.
Is Arrowhead Pharmaceuticals a Buy Now?
Cory Renauer|Apr 16, 2023
The clinical-stage drug developer is attracting a lot of positive attention from investment bank analysts.
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
George Budwell, PhD|Apr 4, 2023
Arrowhead Pharmaceuticals and Seres Therapeutics are screaming buys, according to some Wall Street analysts.
3 No-Brainer Stocks to Buy Right Now for Less Than $25
James Halley|Feb 4, 2023
All three healthcare stocks are showing solid long-term potential.
3 Biotech Stocks That Could Go Parabolic in 2022
George Budwell, PhD|Jan 17, 2022
Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Viking Therapeutics could be big winners this year.
4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout
Cory Renauer|Nov 23, 2021
The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.
Arrowhead Pharmaceuticals: Buy the Dip?
Zhiyuan Sun|Jul 19, 2021
This biotech underdog offers more than meets the eye.
